Kliinilised ja prekliinilised uuringud
Uuringud kinnitavad, et Femarelle on efektiivne paljude menopausi sümptomite korral, omab positiivset toimet luude tugevuse säilitamisel, ei mõjuta rinnanäärmeid, emakat ega vere hüübivust ning sellel puuduvad negatiivsed kõrvalmõjud.
Femarellet on palju uuritud ja hinnatud selle efektiivsust ning ohutust. Need uuringud on läbi viidud maailma juhtivate menopausi ja naiste tervise ekspertide poolt. Tänaseks on publitseeritud üle 20 kliinilise ja prekliinilise uuringu tulemuse, samuti on Femarelle uuringute tulemusi esitletud 30 teaduskonverentsil üle maailma.
Järgnevalt on ära toodud Femarelle uuringute tulemused, mis peaksid eelkõige huvi pakkuma arstidele ja meditsiinitudengitele.
-
DT56a (Femarelle): A natural selective estrogen receptor modulator (SERM)
D. Somjen, I. Yoles
Journal of Steroid Biochemistry & Molecular Biology 104 (2007) 252–258
Full report Summary
-
Efficacy and safety of standard versus low-dose Femarelle (Tofupill) for the treatment of menopausal symptoms
I. Yoles et al.
Journal of Clinical and Experimental Obstetrics & Gynecology 31[2] (2004) 123-126
Full report Summary
-
Tofupill/Femarelle(DT56a): a new phyto-selective estrogen receptor modulator-like substance for the treatment of postmenopausal bone loss
I. Yoles et al.
Menopause: The Journal of The North American Menopause Society 10[6] (2003) 522-525
Full report Summary -
DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus
D. Somjen, I. Yoles
Journal of Steroid Biochemistry & Molecular Biology 86[1] (2003) 93-98
Full report Summary
-
DT56a (Femarelle) stimulates bone formation in female rats
D. Somjen, I. Yoles et al.
British Journal of Obstetrics & Gynecology 112[7] (2005) 981-85
Full report Summary
-
Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract
M.V. Oropeza, S. Orozco, H. Ponce, M.G. Campos
Reproductive Toxicology 20[2] (2005) 261-66
Full report Summary
-
DT56a stimulates gender-specific human cultured bone cells in vitro
D. Somjen, S. Katzburg, M. Lieberherr, D. Hendel, I. Yoles
Journal of Steroid Biochemistry & Molecular Biology 98[1] (2006) 90-96
Full report Summary
-
Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cell-line
I. Yoles, G. Lilling
European Journal of Obstetrics & Gynecology and Reproductive Biology 130[1] (2007) 140-141
Full report
-
Femarelle, a novel SERM for the treatment of menopause, did not affect the clotting time of either normal or thrombophilic postmenopausal women
M. Nachtigall et al.
Menopause: The Journal of The North American Menopause Society 15[6] (2008) 1220
Full report
-
Brain-region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats
A.R. Genazzani et al.
Menopause: The Journal of The North American Menopause Society 16[5] (2009) 1027-43
Full report Summary
-
Femarelle, the first line treatment for the management of menopause
L. Nachtigall
Journal of Gynecological Endocrinology 2008 24[1] (2008) 77-78
Full report
-
DT56a stimulates creatine kinase specific activity in vascular tissues of rats
D. Somjen, I. Yoles
Journal of Endocrinological Investigation 26[10] (2003) 966-971
Full report Summary
-
The effect of DT56a (Femarelle) and other isolated isoflavones on bone architecture of ovariectomized female rats
I.Yoles, D. Somjen
Menopause: The Journal of The North American Menopause Society 12[6] (2005) 815
Full report Summary
Esindaja Eestis: AnkaMedical OÜ, Raua 41, Tallinn info@ankamedical.ee
Tootja: Se-Cure Pharmaceuticals Ltd, P.O.Box 299, Airport City 70100, Israel www.femarelle.com